SG11201901206SA - Trimer stabilizing hiv envelope protein mutations - Google Patents
Trimer stabilizing hiv envelope protein mutationsInfo
- Publication number
- SG11201901206SA SG11201901206SA SG11201901206SA SG11201901206SA SG11201901206SA SG 11201901206S A SG11201901206S A SG 11201901206SA SG 11201901206S A SG11201901206S A SG 11201901206SA SG 11201901206S A SG11201901206S A SG 11201901206SA SG 11201901206S A SG11201901206S A SG 11201901206SA
- Authority
- SG
- Singapore
- Prior art keywords
- archimedesweg
- leiden
- international
- rule
- hiv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0111010101111101111101 0 01111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2018/050747 Al 22 March 2018 (22.03.2018) WIP0 I PCT (51) International Patent Classification: Declarations under Rule 4.17: A61K 39/12 (2006.01) C07K 14/005 (2006.01) — as to applicant's entitlement to apply for and be granted a (21) International Application Number: patent (Rule 4.17(ii)) PCT/EP2017/073141 — of inventorship (Rule 4.17(iv)) (22) International Filing Date: Published: 14 September 2017 (14.09.2017) — with international search report (Art. 21(3)) — (25) Filing Language: English before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (26) Publication Language: English amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) (30) Priority Data: 16188866.4 15 September 2016 (15.09.2016) EP (71) Applicant: JANSSEN VACCINES & PREVENTION B.V. [NL/NL]; Archimedesweg 4, 2333 CN Leiden (NL). (72) Inventors: RUTTEN, Lucy; Archimedesweg 4-6, 2333 CN Leiden (NL). TRUAN, Daphne; Archimedesweg 4-6, 2333 CN Leiden (NL). STROKAPPE, Nika, Mindy; Archimedesweg 4-6, 2333 CN Leiden (NL). _ LANGEDIJK, Johannes, Petrus, Maria; Archimedesweg 4-6, 2333 CN Leiden (NL). — = Agent: VERHAGE, Richard, A et al.; Archimedesweg (74) 4-6, 2333 CN Leiden (NL). = Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (81) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. _ Designated States (unless otherwise indicated, for every — (84) _ _ kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, — MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = 1-1 IN 71- (54) Title: TRIMER STABILIZING HIV ENVELOPE PROTEIN MUTATIONS IN 0 (57) : Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the en- i ln 0 velope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope ----- protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved GC trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also 1-1 © provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV f'1 envelope proteins, nucleic acid, and vectors. 0
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16188866 | 2016-09-15 | ||
PCT/EP2017/073141 WO2018050747A1 (en) | 2016-09-15 | 2017-09-14 | Trimer stabilizing hiv envelope protein mutations |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901206SA true SG11201901206SA (en) | 2019-04-29 |
Family
ID=57017955
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202001956UA SG10202001956UA (en) | 2016-09-15 | 2017-09-14 | Trimer stabilizing hiv envelope protein mutations |
SG11201901206SA SG11201901206SA (en) | 2016-09-15 | 2017-09-14 | Trimer stabilizing hiv envelope protein mutations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202001956UA SG10202001956UA (en) | 2016-09-15 | 2017-09-14 | Trimer stabilizing hiv envelope protein mutations |
Country Status (30)
Country | Link |
---|---|
US (3) | US10793607B2 (en) |
EP (2) | EP3747463A1 (en) |
JP (2) | JP7178344B2 (en) |
KR (1) | KR102513146B1 (en) |
CN (1) | CN109689091A (en) |
AR (1) | AR109528A1 (en) |
AU (2) | AU2017327672B2 (en) |
BR (1) | BR112019004593A2 (en) |
CA (1) | CA3036959A1 (en) |
CY (1) | CY1124518T1 (en) |
DK (1) | DK3512543T3 (en) |
EA (1) | EA201990715A1 (en) |
ES (1) | ES2824525T3 (en) |
HR (1) | HRP20201458T1 (en) |
HU (1) | HUE052008T2 (en) |
IL (2) | IL265186B (en) |
LT (1) | LT3512543T (en) |
MA (1) | MA46230B1 (en) |
MD (1) | MD3512543T2 (en) |
MX (1) | MX2019002938A (en) |
MY (1) | MY190534A (en) |
PH (1) | PH12019500280A1 (en) |
PL (1) | PL3512543T3 (en) |
PT (1) | PT3512543T (en) |
RS (1) | RS60919B1 (en) |
SG (2) | SG10202001956UA (en) |
SI (1) | SI3512543T1 (en) |
TW (1) | TWI742158B (en) |
WO (1) | WO2018050747A1 (en) |
ZA (1) | ZA201901597B (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA038974B1 (en) | 2015-12-15 | 2021-11-17 | Янссен Вэксинс Энд Превеншн Б.В. | Human immunodeficiency virus antigens, vectors, compositions and methods of use thereof |
CA3016352A1 (en) | 2016-03-03 | 2017-09-08 | Duke University | Compositions and methods for inducing hiv-1 antibodies |
US11318197B2 (en) | 2016-03-03 | 2022-05-03 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
CN109153704A (en) * | 2016-05-02 | 2019-01-04 | 斯克里普斯研究学院 | Composition relevant to HIV-1 immunogene and method |
AU2017286375B2 (en) | 2016-06-16 | 2019-04-18 | Janssen Vaccines & Prevention B.V. | HIV vaccine formulation |
AU2017318689A1 (en) | 2016-09-02 | 2019-04-11 | Beth Israel Deaconess Medical Center, Inc. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
DK3512543T3 (en) | 2016-09-15 | 2020-10-12 | Janssen Vaccines & Prevention Bv | TRIMER STABILIZING MUTATIONS OF HIV CAPTAIN PROTEIN |
CA3039089A1 (en) | 2016-10-03 | 2018-04-12 | Duke University | Methods to identify immunogens by targeting improbable mutations |
EA202090049A1 (en) | 2017-06-15 | 2020-04-15 | Янссен Вэксинс Энд Превеншн Б.В. | POXVIRUS VECTORS CODING HIV ANTIGENES AND WAYS OF THEIR APPLICATION |
AU2018304502B2 (en) * | 2017-07-19 | 2022-03-31 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing HIV envelope protein mutations |
SG11202012313PA (en) | 2018-06-13 | 2021-01-28 | Scripps Research Inst | Nanoparticle vaccines with novel structural components |
EA038287B1 (en) * | 2018-06-18 | 2021-08-04 | Янссен Вэксинс Энд Превеншн Б.В. | Trimer stabilizing hiv envelope protein mutations |
US20210379177A1 (en) * | 2018-10-01 | 2021-12-09 | Duke University | Hiv-1 envelope stabilizing mutations |
CN114206103A (en) * | 2019-01-22 | 2022-03-18 | 蓝鸟生物公司 | Method and system for producing viral vectors |
CN110184298B (en) * | 2019-05-15 | 2023-05-16 | 武汉璟泓科技股份有限公司 | HIV mutant type surface glycoprotein, nano antigen and preparation method thereof |
US20220401546A1 (en) * | 2019-11-14 | 2022-12-22 | Emory University | HIV Immunogens, Vaccines, and Methods Related Thereto |
EP4245767A1 (en) * | 2020-11-12 | 2023-09-20 | Xiamen University | Modified membrane protein of human immunodeficiency virus and use thereof |
KR20230150269A (en) | 2021-02-23 | 2023-10-30 | 얀센 백신스 앤드 프리벤션 비.브이. | Trimer stabilizing HIV envelope protein mutations |
WO2023156505A1 (en) | 2022-02-17 | 2023-08-24 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l |
WO2023192835A1 (en) * | 2022-03-27 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Base-covered hiv-1 envelope ectodomains and their use |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
US5761893A (en) | 1996-10-22 | 1998-06-09 | Lofquist Welding, Inc. | Crop saving attachment for the snouts of combines |
US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
EP1214333A4 (en) | 1999-09-17 | 2005-01-19 | Dana Farber Cancer Inst Inc | Stabilized soluble glycoprotein trimers |
UA76731C2 (en) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Mva-bn strain of modified vaccinia ankara virus, pharmaceutical composition, vaccine, use of mva-bn strain for vaccine preparation, method for transfer of homologous and/or heterologous nucleic acid sequence into the target cells in vitro, method for preparing peptide or protein, method for obtaining mva-bn strain, host cell, set for primary/buster immunization |
CN101397574A (en) | 2001-12-04 | 2009-04-01 | 巴法里安诺迪克有限公司 | Flavivirus NS1 subunit vaccine |
IL164803A0 (en) | 2002-04-25 | 2005-12-18 | Crucell Holland Bv | Means and methods for the production of adenovirusvectors |
WO2004044155A2 (en) | 2002-11-07 | 2004-05-27 | Beth Israel Deaconess Medical Center | MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
CA2505583C (en) | 2002-12-03 | 2014-07-15 | University Of Massachusetts | Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods |
EP2359851A3 (en) | 2003-03-28 | 2011-08-31 | The Government of the United States of America, represented by The Secretary, Department of Health and Human Services | MVA expressing modified hiv envelope, gag, and pol genes |
CA2539021A1 (en) | 2003-09-15 | 2005-03-31 | Chiron Corporation | Combination approaches for generating immune responses |
JP4773352B2 (en) * | 2003-09-17 | 2011-09-14 | デューク ユニバーシティ | Consensus / ancestral immunogen |
WO2005052119A2 (en) | 2003-11-19 | 2005-06-09 | Beth Israel Deaconess Medical Center | Adjuvants of immune response |
US20080274134A1 (en) | 2004-06-15 | 2008-11-06 | Norbert Schulke | Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex |
CN101277971A (en) | 2004-07-16 | 2008-10-01 | 美国政府健康及人类服务部 | Vaccines against AIDS comprising CMV/R - nucleic acid constructs |
WO2006040330A2 (en) | 2004-10-13 | 2006-04-20 | Crucell Holland B.V. | Improved adenoviral vectors and uses thereof |
CN1857345B (en) * | 2005-05-08 | 2010-09-01 | 谢秀琼 | Hemicrania treating medicine composition and its preparing method |
US20100221241A1 (en) | 2005-07-06 | 2010-09-02 | University Of Maryland Biotechnology Institute | Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
AU2006283101B2 (en) | 2005-08-23 | 2013-03-07 | Beth Israel Deaconess Medical Center | Polyvalent vaccine |
WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
WO2007149491A2 (en) | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Soluble stabilized trimeric hiv env proteins and uses thereof |
US7939083B2 (en) | 2006-10-23 | 2011-05-10 | Progenics Pharmaceuticals Inc. | Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain |
WO2008140579A2 (en) | 2006-11-17 | 2008-11-20 | New York University | Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope |
HUE031411T2 (en) | 2007-03-02 | 2017-07-28 | Glaxosmithkline Biologicals Sa | Novel method and compositions |
LT2340038T (en) | 2008-10-10 | 2018-04-10 | Children`S Medical Center Corporation | Biochemically stabilized hiv-1 env trimer vaccine |
US9017691B2 (en) | 2008-11-18 | 2015-04-28 | Beth Israel Deaconess Medical Center | Antiviral vaccines with improved cellular immunogenicity |
WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
CN102711794B (en) | 2010-01-04 | 2015-11-25 | Kj生物科学有限公司 | For the Dps fusion rotein of vaccine and diagnostics |
DK2529010T3 (en) | 2010-01-28 | 2017-07-24 | Bavarian Nordic As | MUTANTS OF VACCINIAVIRUS CONTAINING THE MAIN GENOMIC DELETIONS OF VAT |
ES2774369T3 (en) | 2010-08-31 | 2020-07-20 | Theraclone Science Int | Neutralization antibody of human immunodeficiency virus |
US20140348791A1 (en) | 2011-09-09 | 2014-11-27 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
EP2766037A4 (en) | 2011-10-12 | 2015-08-05 | Scripps Research Inst | An hiv-1 gp120 mini v3 loop and uses thereof |
US9683268B2 (en) | 2012-09-19 | 2017-06-20 | Beth Israel Deaconess | Viruses associated with immunodeficiency and enteropathy and methods using same |
CN105051198A (en) | 2012-11-16 | 2015-11-11 | 貝丝以色列女执事医疗中心 | Recombinant adenoviruses and use thereof |
CA2897059C (en) | 2013-01-07 | 2021-12-28 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same |
WO2014124301A1 (en) | 2013-02-07 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
US10376583B2 (en) | 2013-09-30 | 2019-08-13 | Beth Israel Deaconess Medical Center, Inc. | Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator |
US10400015B2 (en) | 2014-09-04 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
BR112017005917A2 (en) | 2014-09-26 | 2017-12-12 | Beth Israel Deaconess Medical Ct Inc | processes and compositions for inducing protective immunity against human immunodeficiency virus infection |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
US20180052173A1 (en) | 2015-03-18 | 2018-02-22 | Janssen Vaccines & Prevention B.V. | Assays for recombinant expression systems |
EA038974B1 (en) | 2015-12-15 | 2021-11-17 | Янссен Вэксинс Энд Превеншн Б.В. | Human immunodeficiency virus antigens, vectors, compositions and methods of use thereof |
AU2017286375B2 (en) | 2016-06-16 | 2019-04-18 | Janssen Vaccines & Prevention B.V. | HIV vaccine formulation |
AU2017318689A1 (en) | 2016-09-02 | 2019-04-11 | Beth Israel Deaconess Medical Center, Inc. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
DK3512543T3 (en) | 2016-09-15 | 2020-10-12 | Janssen Vaccines & Prevention Bv | TRIMER STABILIZING MUTATIONS OF HIV CAPTAIN PROTEIN |
AU2018304502B2 (en) * | 2017-07-19 | 2022-03-31 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing HIV envelope protein mutations |
-
2017
- 2017-09-14 DK DK17769027.8T patent/DK3512543T3/en active
- 2017-09-14 PL PL17769027T patent/PL3512543T3/en unknown
- 2017-09-14 SG SG10202001956UA patent/SG10202001956UA/en unknown
- 2017-09-14 CN CN201780054555.6A patent/CN109689091A/en active Pending
- 2017-09-14 ES ES17769027T patent/ES2824525T3/en active Active
- 2017-09-14 RS RS20201208A patent/RS60919B1/en unknown
- 2017-09-14 SI SI201730416T patent/SI3512543T1/en unknown
- 2017-09-14 MX MX2019002938A patent/MX2019002938A/en unknown
- 2017-09-14 EA EA201990715A patent/EA201990715A1/en unknown
- 2017-09-14 BR BR112019004593A patent/BR112019004593A2/en unknown
- 2017-09-14 MA MA46230A patent/MA46230B1/en unknown
- 2017-09-14 HU HUE17769027A patent/HUE052008T2/en unknown
- 2017-09-14 AR ARP170102536A patent/AR109528A1/en unknown
- 2017-09-14 MD MDE20190798T patent/MD3512543T2/en unknown
- 2017-09-14 WO PCT/EP2017/073141 patent/WO2018050747A1/en active Search and Examination
- 2017-09-14 US US15/704,651 patent/US10793607B2/en active Active
- 2017-09-14 JP JP2019514316A patent/JP7178344B2/en active Active
- 2017-09-14 CA CA3036959A patent/CA3036959A1/en active Pending
- 2017-09-14 IL IL265186A patent/IL265186B/en unknown
- 2017-09-14 PT PT177690278T patent/PT3512543T/en unknown
- 2017-09-14 EP EP20179463.3A patent/EP3747463A1/en active Pending
- 2017-09-14 AU AU2017327672A patent/AU2017327672B2/en active Active
- 2017-09-14 MY MYPI2019001242A patent/MY190534A/en unknown
- 2017-09-14 IL IL294832A patent/IL294832A/en unknown
- 2017-09-14 EP EP17769027.8A patent/EP3512543B1/en active Active
- 2017-09-14 KR KR1020197007592A patent/KR102513146B1/en active IP Right Grant
- 2017-09-14 LT LTEP17769027.8T patent/LT3512543T/en unknown
- 2017-09-14 SG SG11201901206SA patent/SG11201901206SA/en unknown
- 2017-09-15 TW TW106131855A patent/TWI742158B/en active
-
2019
- 2019-02-08 PH PH12019500280A patent/PH12019500280A1/en unknown
- 2019-03-14 ZA ZA2019/01597A patent/ZA201901597B/en unknown
-
2020
- 2020-08-13 US US16/947,694 patent/US11365222B2/en active Active
- 2020-09-14 HR HRP20201458TT patent/HRP20201458T1/en unknown
- 2020-10-09 CY CY20201100952T patent/CY1124518T1/en unknown
- 2020-11-13 AU AU2020267278A patent/AU2020267278B2/en not_active Expired - Fee Related
-
2022
- 2022-06-08 US US17/805,873 patent/US11820796B2/en active Active
- 2022-11-14 JP JP2022181566A patent/JP2023011941A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
SG11201807912SA (en) | Vaccine against rsv | |
SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201811603WA (en) | Novel adeno-associated virus capsid proteins | |
SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
SG11201810048VA (en) | Tri-segmented pichinde viruses as vaccine vectors | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201808709VA (en) | T cell receptors | |
SG11201900447SA (en) | Methods and compositions for modifying genomic dna | |
SG11201808750PA (en) | T cell receptors | |
SG11201909432SA (en) | Compounds for increasing genome editing efficiency | |
SG11201810179RA (en) | Novel crispr enzymes and systems | |
SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201811554SA (en) | Antisense oligonucleotides for modulating htra1 expression | |
SG11201803934YA (en) | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |